Sensory neuron voltage-gated sodium channels as analgesic drug targets

Current Opinion in Neurobiology

Volumn 18, Issue 4, 2008, Pages 383-388

  Momin, Aliakmal ^a   Wood, John N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

A 803467; ANALGESIC AGENT; CARBAMEZAPINE; CONOTOXIN; HARKOSERIDE; LIDOCAINE; MEXILITINE; MUO CONOTOXIN; NATURAL PRODUCT; SAXITOXIN; SODIUM CHANNEL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL;

DISEASE CONTROL; ERYTHROMELALGIA; FEASIBILITY STUDY; HUMAN; HYPERALGESIA; MONOTHERAPY; NEUROPATHIC PAIN; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; SENSORY NERVE CELL;

ANALGESICS; ANIMALS; HUMANS; MICE; MICE, TRANSGENIC; PAIN; SENSORY RECEPTOR CELLS; SIGNAL TRANSDUCTION; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 55249124953     PISSN: 09594388     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conb.2008.08.017     Document Type: Review

References (52)

1. Craner M.J., Damarjian T.G., Liu S., Hains B.C., Lo A.C., Black J.A., Newcombe J., Cuzner M.L., and Waxman S.G. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49 (2005) 220-229
2. Scholz J., and Woolf C.J. The neuropathic pain triad: neurons, immune cells and glia 114. Nat Neurosci 10 (2007) 1361-1368
3. Berta T., Poirot O., Pertin M., Ji R.R., Kellenberger S., and Decosterd I. Transcriptional and functional profiles of voltage-gated Na(+) channels in injured and non-injured DRG neurons in the SNI model of neuropathic pain. Mol Cell Neurosci 37 (2008) 196-208
4. Dib-Hajj S.D., Fjell J., Cummins T.R., Zheng Z., Fried K., LaMotte R., Black J.A., and Waxman S.G. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 83 (1999) 591-600
5. Waxman S.G., Kocsis J.D., and Black J.A. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J Neurophysiol 72 (1994) 466-470
6. Boucher T.J., Okuse K., Bennett D.L., Munson J.B., Wood J.N., and McMahon S.B. Potent analgesic effects of GDNF in neuropathic pain states. Science 290 (2000) 124-127
7. Hains B.C., Saab C.Y., Klein J.P., Craner M.J., and Waxman S.G. Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J Neurosci 24 (2004) 4832-4839
8. Lindia J.A., Kohler M.G., Martin W.J., and Abbadie C. Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain 117 (2005) 145-153
9. Nassar M.A., Baker M.D., Levato A., Ingram R., Mallucci G., McMahon S.B., and Wood J.N. Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol Pain 2 (2006) 33
10. Nieto F.R., Entrena J.M., Cendan C.M., Pozo E.D., Vela J.M., and Baeyens J.M. Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. Pain 137 (2008) 520-531
11. Djouhri L., Newton R., Levinson S.R., Berry C.M., Carruthers B., and Lawson S.N. Sensory and electrophysiological properties of guinea-pig sensory neurones expressing Nav 1.7 (PN1) Na+ channel alpha subunit protein. J Physiol 546 (2003) 565-576
12. Nassar M.A., Stirling L.C., Forlani G., Baker M.D., Matthews E.A., Dickenson A.H., and Wood J.N. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci U S A 101 (2004) 12706-12711
13. Yeomans D.C., Levinson S.R., Peters M.C., Koszowski A.G., Tzabazis A.Z., Gilly W.F., and Wilson S.P. Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents. Hum Gene Ther 16 (2005) 271-277
14. Nassar M.A., Levato A., Stirling L.C., and Wood J.N. Neuropathic pain develops normally in mice lacking both Nav1.7 and Nav1.8. Mol Pain 1 (2005) 24
15. Hoyt S.B., London C., Gorin D., Wyvratt M.J., Fisher M.H., Abbadie C., Felix J.P., Garcia M.L., Li X., Lyons K.A., et al. Discovery of a novel class of benzazepinone Na(v)1.7 blockers: potential treatments for neuropathic pain. Bioorg Med Chem Lett 17 (2007) 4630-4634
16. V1.7.
17. Fertleman C.R., Baker M.D., Parker K.A., Moffatt S., Elmslie F.V., Abrahamsen B., Ostman J., Klugbauer N., Wood J.N., Gardiner R.M., and Rees M. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52 (2006) 767-774. The finding that PEPD, like erythermalgia, also maps to the SCN9A gene was a surprise, and this analysis providing evidence that channel inactivation rather than activation is aberrant, suggests a potential explanation for the differences in symptoms between PEPD and erythermalgia.
18. V1.7 a perfectly validated analgesic drug target.
19. Cummins T.R., Sheets P.L., and Waxman S.G. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain 131 (2007) 243-257
20. Dib-Hajj S.D., Rush A.M., Cummins T.R., Hisama F.M., Novella S., Tyrrell L., Marshall L., and Waxman S.G. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 128 (2005) 1847-1854
21. V1.7 channel is expressed defines its effects on excitability. This is an important observation in terms of screening strategies for identifying channel blockers, and in demonstrating the interrelationships between sodium channels in determining neuronal excitability.
22. Han C., Lampert A., Rush A.M., Dib-Hajj S.D., Wang X., Yang Y., and Waxman S.G. Temperature dependence of erythromelalgia mutation L858F in sodium channel Nav1.7. Mol Pain 3 (2007) 3
23. Ahmad S., Dahllund L., Eriksson A.B., Hellgren D., Karlsson U., Lund P.E., Meijer I.A., Meury L., Mills T., Moody A., et al. A stop codon mutation in SCN9A causes lack of pain sensation. Hum Mol Genet 16 (2007) 2114-2121
24. Goldberg Y.P., MacFarlane J., MacDonald M.L., Thompson J., Dube M.P., Mattice M., Fraser R., Young C., Hossain S., Pape T., et al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet 71 (2007) 311-319
25. Akopian A.N., Souslova V., England S., Okuse K., Ogata N., Ure J., Smith A., Kerr B.J., McMahon S.B., Boyce S., et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 2 (1999) 541-548
26. Renganathan M., Cummins T.R., and Waxman S.G. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J Neurophysiol 86 (2001) 629-640
27. V1.8 alone amongst sodium channels remains functional at low temperatures provides one explanation for the nociceptor-specific pattern of expression of this kinetically unusual sodium channel.
28. Khasar S.G., Gold M.S., and Levine J.D. A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat. Neurosci Lett 256 (1998) 17-20
29. Joshi S.K., Mikusa J.P., Hernandez G., Baker S., Shieh C.C., Neelands T., Zhang X.F., Niforatos W., Kage K., Han P., et al. Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain 123 (2006) 75-82
30. Lai J., Gold M.S., Kim C.S., Bian D., Ossipov M.H., Hunter J.C., and Porreca F. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain 95 (2002) 143-152
31. Dong X.W., Goregoaker S., Engler H., Zhou X., Mark L., Crona J., Terry R., Hunter J., and Priestley T. Small interfering RNA-mediated selective knockdown of Na(V)1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience 146 (2007) 812-821
32. Kerr B.J., Souslova V., McMahon S.B., and Wood J.N. A role for the TTX-resistant sodium channel Nav 1.8 in NGF-induced hyperalgesia, but not neuropathic pain. Neuroreport 12 (2001) 3077-3080
33. V1.8 as a useful analgesic drug target.
34. Dib-Hajj S.D., Tyrrell L., and Waxman S.G. Structure of the sodium channel gene SCN11A: evidence for intron-to-exon conversion model and implications for gene evolution. Mol Neurobiol 26 (2002) 235-250
35. Amaya F., Wang H., Costigan M., Allchorne A.J., Hatcher J.P., Egerton J., Stean T., Morisset V., Grose D., Gunthorpe M.J., et al. The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J Neurosci 26 (2006) 12852-12860
36. Priest B.T., Murphy B.A., Lindia J.A., Diaz C., Abbadie C., Ritter A.M., Liberator P., Iyer L.M., Kash S.F., Kohler M.G., et al. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel NaV1.9 to sensory transmission and nociceptive behaviour. Proc Natl Acad Sci U S A 102 (2005) 9382-9387
37. Ostman J.A., Nassar M.A., Wood J.N., and Baker M.D. GTP up-regulated persistent Na+ current and enhanced nociceptor excitability require NaV1.9. J Physiol 586 (2008) 1077-1087
38. Baker M.D. Protein kinase C mediates up-regulation of tetrodotoxin-resistant, persistent Na+ current in rat and mouse sensory neurones. J Physiol 567 (2005) 851-867
39. Blum R., Kafitz K.W., and Konnerth A. Neurotrophin-evoked depolarization requires the sodium channel Na(V)1.9. Nature 419 (2002) 687-693
40. Leffler A., Herzog R.I., Dib-Hajj S.D., Waxman S.G., and Cummins T.R. Pharmacological properties of neuronal TTX-resistant sodium channels and the role of a critical serine pore residue. Pflugers Arch 451 (2005) 454-463
41. Padilla F., Couble M.L., Coste B., Maingret F., Clerc N., Crest M., Ritter A.M., Magloire H., and Delmas P. Expression and localization of the Nav1.9 sodium channel in enteric neurons and in trigeminal sensory endings: implication for intestinal reflex function and orofacial pain. Mol Cell Neurosci 35 (2007) 138-152
42. Rugiero F., Mistry M., Sage D., Black J.A., Waxman S.G., Crest M., Clerc N., Delmas P., and Gola M. Selective expression of a persistent tetrodotoxin-resistant Na+ current and NaV1.9 subunit in myenteric sensory neurons. J Neurosci 23 (2003) 2715-2725
43. Martinez V., and Melgar S. Lack of colonic inflammation-induced acute visceral hypersensitivity to colorectal distension in Na(v)1.9 knockout mice. Eur J Pain 12 (2008) 934-944
44. McGaraughty S., Chu K.L., Scanio M.J., Kort M.E., Faltynek C.R., and Jarvis M.F. A selective Nav1.8 sodium channel blocker, A-803467 [5-(4-chlorophenyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic rats. J Pharmacol Exp Ther 324 (2008) 1204-1211
45. Bulaj G., Zhang M.M., Green B.R., Fiedler B., Layer R.T., Wei S., Nielsen J.S., Low S.J., Klein B.D., Wagstaff J.D., et al. Synthetic muO-conotoxin MrVIB blocks TTX-resistant sodium channel NaV1.8 and has a long-lasting analgesic activity. Biochemistry 45 (2006) 7404-7414
46. Ekberg J., Jayamanne A., Vaughan C.W., Aslan S., Thomas L., Mould J., Drinkwater R., Baker M.D., Abrahamsen B., Wood J.N., et al. muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc Natl Acad Sci U S A 103 (2006) 17030-17035
47. Stohr T., Krause E., and Selve N. Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur J Pain 10 (2006) 241-249
48. Beyreuther B., Callizot N., and Stohr T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol 539 (2006) 64-70
49. Beyreuther B.K., Callizot N., Brot M.D., Feldman R., Bain S.C., and Stohr T. Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. Eur J Pharmacol 565 (2007) 98-104
50. Doty P., Rudd G.D., Stoehr T., and Thomas D. Lacosamide. Neurotherapeutics 4 (2007) 145-148
51. Errington A.C., Stohr T., Heers C., and Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 73 (2008) 157-169. An interesting analysis of the actions of lacosamide that provides a mechanism for its broad spectrum blockade of sodium channels.
52. Sheets P.L., Heers C., Stoehr T., and Cummins T.R. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide, lidocaine and carbamazepine. J Pharmacol Exp Ther 326 (2008) 89-99